Navigation Links
OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
Date:6/17/2010

REDWOOD CITY, Calif., June 17 /PRNewswire/ -- OncoMed Pharmaceuticals, Inc. and Bayer Schering Pharma AG, Germany, today announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway.  Cancer stem cells are a subset of tumor cells believed to play a significant role in the establishment, metastasis and recurrence of cancer.  

The strategic alliance leverages OncoMed's leadership in cancer stem cell drug discovery and development.  Under the terms of the agreement, Bayer and OncoMed will develop antibodies, protein therapeutics, and small molecules as potential novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway.  In addition to an upfront cash payment of $40 million, OncoMed is eligible to receive cash payments for product candidates that Bayer Schering Pharma options and possible additional payments upon achievement of certain development and commercialization milestones described below.  The collaboration could potentially include up to five compounds. The agreement includes potential significant near-term milestone payments from Bayer.

OncoMed will utilize its proprietary human cancer stem cell models to discover and advance antibody and protein therapeutics through Phase I clinical studies.  Bayer Schering Pharma receives an option to exclusively license antibody and protein therapeutic product candidates at any point up to the completion of Phase I testing.  Following option exercise, Bayer will lead development and commercialization of licensed product candidates.  For each biotherapeutic drug candidate successfully developed through Phase III clinical trials and regulatory approval, OncoMed's payments
'/>"/>

SOURCE OncoMed Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
2. OncoMed Pharmaceuticals Appoints Sunil Patel Senior Vice President, Corporate Development
3. OncoMed Pharmaceuticals Completes Series B Financing
4. Oramed Pharmaceuticals was Chosen to Present Two Abstracts at the 70th Scientific Sessions of the American Diabetes Association in Orlando, FL, June 25-29, 2010
5. Isis Pharmaceuticals to Discuss Its Neurodegenerative Franchise in a Conference Call on Thursday, June 17
6. Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer
7. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
8. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
9. Amylin Pharmaceuticals to Present at the 2010 Jefferies Global Life Sciences Conference
10. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
11. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Wheaton, Illinois (PRWEB) May 04, 2015 ... treatment options for patients with arm and hand ... rehabilitation exoskeleton at its Oakbrook Terrace network site. ... foundation, the Armeo®Spring is a highly-regarded treatment option ... In acquiring the Armeo®Spring, Marianjoy becomes one of ...
(Date:5/1/2015)... 2015 OncoTAb, Inc., a ... company, announced that Pinku Mukherjee, Ph.D. has received the ... of Governors’ highest faculty honor. Mukherjee received the award, ... for her innovative research and development of cancer diagnostics ... a crowning moment in my scientific career,” said Mukherjee, ...
(Date:5/1/2015)... 2015 Pfenex Inc. (NYSE MKT: PFNX), ... of biosimilar therapeutics including high value and difficult ... quarter 2015 financial results will be released on ... market. At 8:30 am Eastern Time, Pfenex management will ... results and provide a business update. A press release ...
(Date:5/1/2015)... , May 1, 2015 A ... for antithrombotic drugs will reach $22.4bn in 2019. That ... World Industry and Market Prospects 2015-2025 , ... that investigation is to provide forecasts and qualitative analyses ... information publisher and consultancy in London, UK ...
Breaking Biology Technology:Marianjoy Acquires Armeo®Spring Arm and Hand Rehabilitation Exoskeleton at Oakbrook Terrace Facility 2OncoTAb CSO Awarded the University of North Carolina’s O. Max Gardner Award 2Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5
... , London, July 20 There ... in the pharmaceutical and biotechnology space. While the economic downturn and ... for the recent M&A mania, which has including four mega M&As ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , , ...
... , EDMONTON, July 17 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: ... (MS), today announced financial and operational results for the three ... phase III MAESTRO-01 trial has completed the last patient last ... the second half of this year. This is the first ...
... 17 Encorium Group, Inc. (Nasdaq: ... organization (CRO) that provides design, development, and management capabilities ... the world,s leading pharmaceutical companies, today announced that is ... U.S. business to Pierrel Research USA, Inc., a wholly-owned ...
Cached Biology Technology:Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities 2BioMS Medical announces second quarter 2009 results 2BioMS Medical announces second quarter 2009 results 3BioMS Medical announces second quarter 2009 results 4BioMS Medical announces second quarter 2009 results 5BioMS Medical announces second quarter 2009 results 6BioMS Medical announces second quarter 2009 results 7BioMS Medical announces second quarter 2009 results 8BioMS Medical announces second quarter 2009 results 9Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes 2Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes 3Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes 4
(Date:4/8/2015)... 8, 2015  Infinisource, a leading provider of SaaS-based ... Morpho, a leading supplier of biometric identification and ... market,s most advanced biometrically-enabled time clock, the companies ... clock is setting a bold, new standard for ... the small and mid-size employer. When connected to ...
(Date:4/2/2015)... , April 2, 2015 At its ... Salt Lake City , the American College of ... five new directors to its Board.  Members of the ... ACMG and for forming and advancing its policies and ... genetics profession. "It,s an eventful time in ...
(Date:4/1/2015)... , Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... Wocket smart wallets is underway to early access pre-order ... group includes usage at retail outlets including Walmart, Target, ... Users report Wocket was accepted at all outlets and ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4
... Technologies was chosen for multiple reasons: to initiate a ... provide society with security of energy supply and to ... a European graduate school is thought to be the ... to foster the development of excellent young scientists, presenting ...
... of years, humans have evolved to naturally understand things like ... researcher has found there is an ever-widening gap between what ... to be successful adults in today,s modern society. Schools have ... but in the U.S. more may need to be done. ...
... Netherlands, June 09, 2009 / b3c newswire / ... the Netherlands Organisation for Applied Scientific Research TNO today ... to further develop Amarna’s viral gene delivery platform ... methods for the manufacture, formulation and testing of viral ...
Cached Biology News:MU study finds connection between evolution, classroom learning 2Amarna Therapeutics B.V. and TNO announce SVac research and development partnership 2Amarna Therapeutics B.V. and TNO announce SVac research and development partnership 3
... Dithiothreitol DTT White solid.. PACKAGED UNDER ... thiols, so reaction is "driven" to completion. A ... waxy surfactant found in many other preparations. Blocks ... Purity: ≥97% by titration. Contaminants: Heavy ...
... to help promote genomics-based research with S. aureus, ... that contains PCR primers to amplify all open ... addition, primer pairs are included to amplify ORFs ... N315 strains of S. aureus. The ORFmer set ...
... makes your life easier. It offers a wide array ... one balance. *Instruments supported: ... AG, XS, XP, PR, SR, PG-S, PG, SG, AT, ... User guidance on the ...
High affinity antibody reacting with S-100 ab heterodimer. Could be used for Western blotting application and immunoassay....
Biology Products: